Abstract
Background: Anti-inflammatory drugs can be ineffective in treating some inflammatory conditions. Improved drug delivery systems like cyclodextrins (CDs) could enhance their efficacy and safety.
Objective: We conducted a systematic review to evaluate the anti-inflammatory activity of compounds complexed in CDs, analyzing whether these complexes improved their pharmacological action. Methods: The search terms ‘Anti-inflammatory Agents’, ‘Cyclodextrins’ and ‘Drug effects’ were used to retrieve articles in SCOPUS, PUBMED, MEDLINE and EMBASE. Results: Forty-four papers were identified. In the in vivo and clinical studies, there was greater efficacy for complexed drugs when compared to control groups or uncomplexed drug, decreasing inflammation and inflammatory mediators. Through a meta-analysis, the preclinical studies demonstrated that the complexed drug had a significantly (p<0.001) greater anti-inflammatory effect than the non-CD-complexed drug. Conclusion: The use of CDs can improve the action of anti-inflammatory compounds and it can also be a way to reduce the side effects, therapeutic doses and toxicity.Keywords: Anti-inflammatory agents, cyclodextrins, drug effects, inflammation, systematic review, meta-analysis.
Current Pharmaceutical Design
Title:Cyclodextrins as Complexation Agents to Improve the Anti-inflammatory Drugs Profile: a Systematic Review and Meta-Analysis
Volume: 23 Issue: 14
Author(s): Priscila L. Santos, Renan G. Brito, Jullyana S.S. Quintans, Adriano A.S. Araujo, Irwin R.A. Menezes, Nicole K. Brogden and Lucindo J. Quintans-Junior*
Affiliation:
- Laboratory of Neuroscience and Pharmacological Assays (LANEF), Federal University of Sergipe, Av. Marechal Rondon, s/n, São Cristóvão, Sergipe, CEP: 49.100-000,Brazil
Keywords: Anti-inflammatory agents, cyclodextrins, drug effects, inflammation, systematic review, meta-analysis.
Abstract: Background: Anti-inflammatory drugs can be ineffective in treating some inflammatory conditions. Improved drug delivery systems like cyclodextrins (CDs) could enhance their efficacy and safety.
Objective: We conducted a systematic review to evaluate the anti-inflammatory activity of compounds complexed in CDs, analyzing whether these complexes improved their pharmacological action. Methods: The search terms ‘Anti-inflammatory Agents’, ‘Cyclodextrins’ and ‘Drug effects’ were used to retrieve articles in SCOPUS, PUBMED, MEDLINE and EMBASE. Results: Forty-four papers were identified. In the in vivo and clinical studies, there was greater efficacy for complexed drugs when compared to control groups or uncomplexed drug, decreasing inflammation and inflammatory mediators. Through a meta-analysis, the preclinical studies demonstrated that the complexed drug had a significantly (p<0.001) greater anti-inflammatory effect than the non-CD-complexed drug. Conclusion: The use of CDs can improve the action of anti-inflammatory compounds and it can also be a way to reduce the side effects, therapeutic doses and toxicity.Export Options
About this article
Cite this article as:
Santos L. Priscila, Brito G. Renan, Quintans S.S. Jullyana, Araujo A.S. Adriano, Menezes R.A. Irwin, Brogden K. Nicole and Quintans-Junior J. Lucindo*, Cyclodextrins as Complexation Agents to Improve the Anti-inflammatory Drugs Profile: a Systematic Review and Meta-Analysis, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170126121926
DOI https://dx.doi.org/10.2174/1381612823666170126121926 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice
Current Genomics Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer
Current Cancer Drug Targets Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
Current Cancer Drug Targets MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Molecular Properties and Medical Applications of Peptide Nucleic Acids
Mini-Reviews in Medicinal Chemistry Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Current Development of Metal Complexes with Diamine Ligands as Potential Anticancer Agents
Current Medicinal Chemistry Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics